Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous platelet-rich plasma + autologous platelet-poor plasma eye drops
- Development stage
- Unknown
- Lead developer
- Ladan Espandar
- Modality
- Cell Therapies
- Administration
- Ophthalmic
01
Overview
Autologous platelet-rich plasma (PRP) and platelet-poor plasma (PPP) eye drops are biological products derived from a patient's own peripheral blood, specifically formulated for the treatment of ocular graft-versus-host disease (O-GVHD). Developed and investigated by Ladan Espandar, this therapy involves the concentration of platelets to harness their alpha-granules, which release a variety of growth factors and cytokines, including platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-β), and epidermal growth factor (EGF). These components facilitate corneal epithelial cell proliferation and migration, promote wound healing, and provide anti-inflammatory support to the ocular surface. The treatment protocol typically involves a sequential application of PRP followed by PPP to maximize the regenerative potential of the plasma components.
- Other names
- PRP eye dropsPPP eye dropsautologous platelet-rich plasmaautologous platelet-poor plasma
Beyond the preview
Go deeper on autologous platelet-rich plasma + autologous platelet-poor plasma eye drops.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous platelet-rich plasma + autologous platelet-poor plasma eye drops.